

PHARMACEUTICAL COMPOSITION

Patent number: JP2001089368
Publication date: 2001-04-03
Inventor: YLLA SAAKAA; KURISUJAN S GUDOMANDOSON; RICHARD MARTIN
Applicant: TANABE SEIYAKU CO
Classification:
- international: A61K31/198; A61P1/04; A61P3/10; A61P11/06; A61P17/02; A61P29/00; C07D207/06; C07D213/26; C07D241/12; C07D261/08; C07D277/24; C07D295/14; C07D307/81; C07D333/24; A61K31/185; A61P1/00; A61P3/00; A61P11/00; A61P17/00; A61P29/00; C07D207/00; C07D213/00; C07D241/00; C07D261/00; C07D277/00; C07D295/00; C07D307/00; C07D333/00; (IPC1-7): C07D207/06; C07D213/26; C07D241/12; C07D261/08; C07D277/24; C07D295/14; C07D307/81; C07D333/24; A61K31/198; A61P1/04; A61P3/10; A61P11/06; A61P17/02; A61P29/00
- european:
Application number: JP20000216898 20000718
Priority number(s): JP20000216898 20000718; JP19990204581 19990719

Report a data error here

Abstract of JP2001089368

PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition useful for treatment of diseases accompanying α 4 mediated cell adhesion. **SOLUTION:** The pharmaceutical composition includes a compound expressed by formula (I) (ring A is an aromatic hydrocarbon ring or the like; Q is a bonding group or the like; n is 0, 1 or 2; W is O, S, -CH=CH= or -N=CH-; Z is O or S; R1, R2 and R3 are each H, a halogen, a (substituted) lower alkyl or the like; R4 is a tetrazolyl, carboxyl or the like; R5 is H, nitro, a (substituted) amino, OH, a lower alkanoyl or the like; R6 is a (substituted) phenyl or the like), remedially effective dose of its pharmaceutically permissible salt and its pharmaceutically permissible support as the active ingredients. The composition is useful for treatment of disease accompanying α 4 mediated cell adhesion such as asthma, diabetic, rheumatic joint disease, inflammatory bowel disease and other diseases relating leukocytic infiltration of gastrointestinal tract or other epithelium (e.g. skin, urethra, bronchial tube or joint synovial).

Data supplied from the esp@cenet database - Worldwide